AwesomeCapital: Ultragenyx Collaboration with Regeneron Intriguing, But Own Pipeline Progress Remains Key - Stifel

Saturday, January 8, 2022

Ultragenyx Collaboration with Regeneron Intriguing, But Own Pipeline Progress Remains Key - Stifel

Stifel analyst Dae Gon Ha reiterates a "Buy" rating on shares of Ultragenyx Pharma (NASDAQ: RARE.

https://www.streetinsider.com/Analyst+Comments/Ultragenyx+Pharma+%28RARE%29+Collaboration+with+Regeneron+%28REGN%29+is+Intriguing%2C+But+Own+Pipeline+Progress+Remains+Key+-+Stifel/19435446.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)